在GAN饮食和酒的老鼠中,FGF21删除轻微加剧了肝功能障碍
Peter Aldiss1,2,3, Malte Hasle Nielsen4, Hayley Burm5
1Nottingham Digestive Diseases Centre, Translational Medical Sciences, and the Biodiscovery Institute, University of Nottingham, Nottingham, NG7 2RD, UK. peter.aldiss1@nottingham.ac.uk.
npj metabolic health and disease..
|July 3, 2025
概括
纤维细胞生长因子21 (FGF21) 淘汰老鼠在接受肥胖性饮食时显示肝损伤标志物增加. 这项研究验证了用于代谢性肝病研究的新动物模型.
科学领域:
- 代谢性疾病研究研究.
- 人类疾病的动物建模.
- 肝脏疾病研究 肝脏疾病研究
背景情况:
- 纤维细胞生长因子21 (FGF21) 的类似物正在开发中,用于代谢和与酒精有关的肝病.
- 一个经过验证的动物模型对于研究人类肝脏疾病至关重要.
研究的目的:
- 描述第一个FGF21淘汰赛 (KO) 鼠线的特征.
- 为了验证其作为人类肝脏疾病的转化动物模型的实用性.
主要方法:
- 生成了一个FGF21 KO鼠标模型.
- 暴露于野生型 (WT) 和KO大鼠的食或肥胖性Gubra Amylin NASH (GAN) 饮食12周.
- 评估肝脏参数,体重,血糖特征和MASH组织学终点.
主要成果:
- 被GAN饮食养的FGF21KO大鼠表现出血中氨基酸酶,肝脏重量和肝脏甘油三酸的增加.
- FGF21 KO没有影响体重,血糖特征或MASH组织学特征.
- 发现内源性FGF21不能调节老鼠的饮酒行为.
结论:
- FGF21 KO鼠是研究代谢性肝病的一个有价值的翻译模型.
- 内生FGF21在减轻饮食引起的肝损伤方面发挥作用.
- FGF21不会影响老鼠的饮酒行为.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
263
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
263
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
352
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
352


